Kam Shojania
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kam Shojania has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Juan Antonio Avina-Zubieta
Arthritis Research Canada, Vancouver, Canada
3 shared publications - Kun Huang
Arthritis Research Canada Vancouver Canada
3 shared publications - Madelaine Beckett
Department of Medicine, University of British Columbia, Vancouver, Canada
3 shared publications - Mark Harrison
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
3 shared publications - Nick Bansback
The University of British Columbia
3 shared publications - Norma K. Biln
N.K. Biln, PhD, School of Population and Public Health, Faculty of Medicine, University of British Columbia, BC, Canada
3 shared publications
Latest Publications
- 15 February 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (6) , 659-668
Patient and Rheumatologist Perspectives of the Patient Self-Administered Inflammatory Arthritis Detection Tool: Implementation Considerations, Potential Barriers, and Opportunities
Objective: As part of a research program examining rheumatology referrals in British Columbia, the Patient Self-Administered Inflammatory Arthritis Detection (SAID) Study evaluated the SAID tool, which contains validated patient-completed questionnaires for identifying and prioritizing individuals with inflammatory arthritis, supporting its utility and feasibility. This article reports the perspectives of participating patients and rheumatologists regarding the SAID tool. Methods: A multimethods design was used to collect and analyze patient survey and rheumatologist interview data, with an emphasis on implementation considerations. Ninety-two patients who completed the questionnaires in the Patient SAID Study also provided feedback on their experience. Semistructured interviews were conducted with 3 rheumatologists. Quantitative and qualitative data were analyzed using Microsoft Excel and NVivo to identify usability, relevance, and barriers or enablers to implementing the tool in primary-to-specialist referral. Results: Most patients found the SAID tool easy to log into (85%) and complete (82%). Across diagnostic groups, most (76%) believed it could help their general practitioner assess symptoms but emphasized the need for more nuanced response options and space for elaboration. Rheumatologists viewed the tool as brief, useful, and potentially valuable for triage, especially if integrated at the referral stage. Key barriers included time constraints, false negatives, and lack of integration with electronic medical records. All rheumatologists supported optional implementation led by motivated patients, provided it complemented—not complicated—existing workflows. Conclusion: With targeted modifications and appropriate implementation mechanisms, the SAID tool has the potential to improve the quality of referrals, support triage decision making, and address current gaps in access to rheumatology care within evolving digital health systems.
- 15 February 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (6) , 659-668
Patient and Rheumatologist Perspectives of the Patient Self-Administered Inflammatory Arthritis Detection Tool: Implementation Considerations, Potential Barriers, and Opportunities
Objective: As part of a research program examining rheumatology referrals in British Columbia, the Patient Self-Administered Inflammatory Arthritis Detection (SAID) Study evaluated the SAID tool, which contains validated patient-completed questionnaires for identifying and prioritizing individuals with inflammatory arthritis, supporting its utility and feasibility. This article reports the perspectives of participating patients and rheumatologists regarding the SAID tool. Methods: A multimethods design was used to collect and analyze patient survey and rheumatologist interview data, with an emphasis on implementation considerations. Ninety-two patients who completed the questionnaires in the Patient SAID Study also provided feedback on their experience. Semistructured interviews were conducted with 3 rheumatologists. Quantitative and qualitative data were analyzed using Microsoft Excel and NVivo to identify usability, relevance, and barriers or enablers to implementing the tool in primary-to-specialist referral. Results: Most patients found the SAID tool easy to log into (85%) and complete (82%). Across diagnostic groups, most (76%) believed it could help their general practitioner assess symptoms but emphasized the need for more nuanced response options and space for elaboration. Rheumatologists viewed the tool as brief, useful, and potentially valuable for triage, especially if integrated at the referral stage. Key barriers included time constraints, false negatives, and lack of integration with electronic medical records. All rheumatologists supported optional implementation led by motivated patients, provided it complemented—not complicated—existing workflows. Conclusion: With targeted modifications and appropriate implementation mechanisms, the SAID tool has the potential to improve the quality of referrals, support triage decision making, and address current gaps in access to rheumatology care within evolving digital health systems.
- 1 December 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
The Patient Self-Administered Inflammatory Arthritis Detection Study
Objective: Early diagnosis and treat-to-target strategies improve outcomes for patients with inflammatory arthritis (IA). One approach for reducing diagnostic delay is using standardized patient-completed questionnaires to support referral decisions. This study evaluated the discriminatory referral performance of 2 validated questionnaires in newly referred rheumatology patients in British Columbia, Canada. Methods: Patients completed the Early Inflammatory Arthritis Questionnaire (EIAQ) and Case Finding Axial Spondyloarthritis (CaFaSpA) questionnaire. Predictive scores for IA were calculated using existing algorithms and compared to the reference standard of their rheumatologist diagnosis. Discriminative performance was tested using the area under the receiver-operating characteristics curve (AUC), and diagnostic performance was tested using metrics, including sensitivity and specificity. Exploratory regression models were used to predict IA with different combinations of questionnaire questions. Results: Of 92 participants, 30 (33%) had time-sensitive IA (TS-IA), 35 (38%) other IA, and 27 (29%) non-IA. Time from referral to rheumatologist visits for patients with TS-IA was 44 days (IQR 28-83), 69 (IQR 40-102) for "other IA," 65 (IQR 34-99) for "non-IA," and was longer for women (+ 9 days) and in nonmetropolitan areas (+ 16 days). Only 7 patients had axial spondyloarthritis, precluding discriminative analysis of the CaFaSpA. The EIAQ had an AUC of 0.59 (95% CI 0.49-0.68), sensitivity of 33% (95% CI 19-51%), and specificity of 84% (95% CI 73-91); alternate algorithms based on EIAQ and CaFaSpA questions delivered AUCs up to 0.80 (95% CI 0.68-0.90). Conclusion: The results support the utility and feasibility of routine collection of EIAQ and CaFaSpA questionnaires for discriminating patients with IA from those with non-IA.
- 1 December 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
The Patient Self-Administered Inflammatory Arthritis Detection Study
Objective: Early diagnosis and treat-to-target strategies improve outcomes for patients with inflammatory arthritis (IA). One approach for reducing diagnostic delay is using standardized patient-completed questionnaires to support referral decisions. This study evaluated the discriminatory referral performance of 2 validated questionnaires in newly referred rheumatology patients in British Columbia, Canada. Methods: Patients completed the Early Inflammatory Arthritis Questionnaire (EIAQ) and Case Finding Axial Spondyloarthritis (CaFaSpA) questionnaire. Predictive scores for IA were calculated using existing algorithms and compared to the reference standard of their rheumatologist diagnosis. Discriminative performance was tested using the area under the receiver-operating characteristics curve (AUC), and diagnostic performance was tested using metrics, including sensitivity and specificity. Exploratory regression models were used to predict IA with different combinations of questionnaire questions. Results: Of 92 participants, 30 (33%) had time-sensitive IA (TS-IA), 35 (38%) other IA, and 27 (29%) non-IA. Time from referral to rheumatologist visits for patients with TS-IA was 44 days (IQR 28-83), 69 (IQR 40-102) for "other IA," 65 (IQR 34-99) for "non-IA," and was longer for women (+ 9 days) and in nonmetropolitan areas (+ 16 days). Only 7 patients had axial spondyloarthritis, precluding discriminative analysis of the CaFaSpA. The EIAQ had an AUC of 0.59 (95% CI 0.49-0.68), sensitivity of 33% (95% CI 19-51%), and specificity of 84% (95% CI 73-91); alternate algorithms based on EIAQ and CaFaSpA questions delivered AUCs up to 0.80 (95% CI 0.68-0.90). Conclusion: The results support the utility and feasibility of routine collection of EIAQ and CaFaSpA questionnaires for discriminating patients with IA from those with non-IA.
- Open Access
- 25 April 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (17) , e42251
Hematologic malignancies masquerading as rheumatologic diseases: A case series and review
Rationale: Hematologic malignancies can mimic rheumatologic diseases, presenting a significant diagnostic challenge due to overlapping clinical features. This study highlights 5 cases of hematologic malignancies presenting as rheumatologic disorders and discusses the diagnostic complexities involved. Patient concerns: The patients, aged 64 to 78, presented with diverse rheumatologic symptoms including polyarthritis, vasculitis, Raynaud phenomenon, and systemic symptoms such as weight loss, fatigue, and night sweats. Initial workups suggested rheumatologic diagnoses, leading to delays in recognizing the underlying malignancies. Diagnoses: The diagnostic journey involved extensive laboratory testing, imaging, and, in all cases, bone marrow biopsies, which ultimately revealed hematologic malignancies: angioimmunoblastic T-cell lymphoma (AITL), extranodal marginal zone lymphoma, myelodysplastic syndrome (MDS), and multiple myeloma. Misleading initial findings, such as autoimmune serologies and transient responses to immunosuppressive therapy, complicated the diagnostic process. Interventions: Ultimately, the patients included in this case series benefited from hematological malignancy-specific therapies. Delayed diagnosis impacted the treatment course and outcomes. Outcomes: Outcomes varied: 2 patients achieved symptom control with targeted therapy, while others experienced complications such as infections or disease progression, ultimately leading to mortality in some cases. Patient frustrations underscored the psychologic toll of diagnostic delays. Lessons: Hematologic malignancies can present as atypical or refractory rheumatologic diseases, emphasizing the need for vigilance in patients with unusual clinical courses. Early consideration of malignancy in differential diagnoses, especially with atypical serologic or histopathologic findings, is critical to improving outcomes.
- 25 April 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (17) , e42251
Open AccessHematologic malignancies masquerading as rheumatologic diseases: A case series and review
Rationale: Hematologic malignancies can mimic rheumatologic diseases, presenting a significant diagnostic challenge due to overlapping clinical features. This study highlights 5 cases of hematologic malignancies presenting as rheumatologic disorders and discusses the diagnostic complexities involved. Patient concerns: The patients, aged 64 to 78, presented with diverse rheumatologic symptoms including polyarthritis, vasculitis, Raynaud phenomenon, and systemic symptoms such as weight loss, fatigue, and night sweats. Initial workups suggested rheumatologic diagnoses, leading to delays in recognizing the underlying malignancies. Diagnoses: The diagnostic journey involved extensive laboratory testing, imaging, and, in all cases, bone marrow biopsies, which ultimately revealed hematologic malignancies: angioimmunoblastic T-cell lymphoma (AITL), extranodal marginal zone lymphoma, myelodysplastic syndrome (MDS), and multiple myeloma. Misleading initial findings, such as autoimmune serologies and transient responses to immunosuppressive therapy, complicated the diagnostic process. Interventions: Ultimately, the patients included in this case series benefited from hematological malignancy-specific therapies. Delayed diagnosis impacted the treatment course and outcomes. Outcomes: Outcomes varied: 2 patients achieved symptom control with targeted therapy, while others experienced complications such as infections or disease progression, ultimately leading to mortality in some cases. Patient frustrations underscored the psychologic toll of diagnostic delays. Lessons: Hematologic malignancies can present as atypical or refractory rheumatologic diseases, emphasizing the need for vigilance in patients with unusual clinical courses. Early consideration of malignancy in differential diagnoses, especially with atypical serologic or histopathologic findings, is critical to improving outcomes.
- Open Access
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
The role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still’s disease, and COVID-19 cytokine storm
Cytokine storm syndromes such as hemophagocytic lymphohistiocytosis (HLH), Adult-onset Still’s disease (AOSD), and COVID-19 cytokine storm (CCS) are characterized by markedly elevated inflammatory cytokines. However clinical measurement of serum cytokines is not widely available. This study examined the clinical utility of C-reactive protein (CRP) and ferritin, two inexpensive and widely available inflammatory markers, for distinguishing HLH from AOSD and CCS. This single centre retrospective study included 44 secondary HLH patients, 14 AOSD patients, and 13 CCS patients. Baseline CRP and ferritin measured within 72 h of diagnosis and before administration of corticosteroids or other anti-inflammatory therapies were analyzed. The median CRP in HLH patients was lower than AOSD (71 mg/L vs. 172 mg/L, p < 0.001) and CCS (71 mg/L vs. 121 mg/L, p = 0.0095) patients. Serum ferritin levels were lower in CCS compared to HLH (1,386 µg/L vs. 29,019 µg/L, p < 0.001) and AOSD (11,359 µg/L vs. 29,019 µg/L, p = 0.035). A CRP < 130 mg/L when combined with an HScore > 136 improves the specificity of HScore alone for HLH from 85.2 to 96.3%. Adding CRP < 130 mg/L to ferritin > 15,254 µg/L increases specificity for HLH from 88.9 to 100%. This study demonstrates that median CRP is lower in HLH than in AOSD and CCS, and median ferritin is lower in CCS than in HLH or AOSD. This study demonstrates the clinical utility of these widely available inflammatory markers for distinguishing between different cytokine storm syndromes.
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-8
Open AccessThe role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still’s disease, and COVID-19 cytokine storm
Cytokine storm syndromes such as hemophagocytic lymphohistiocytosis (HLH), Adult-onset Still’s disease (AOSD), and COVID-19 cytokine storm (CCS) are characterized by markedly elevated inflammatory cytokines. However clinical measurement of serum cytokines is not widely available. This study examined the clinical utility of C-reactive protein (CRP) and ferritin, two inexpensive and widely available inflammatory markers, for distinguishing HLH from AOSD and CCS. This single centre retrospective study included 44 secondary HLH patients, 14 AOSD patients, and 13 CCS patients. Baseline CRP and ferritin measured within 72 h of diagnosis and before administration of corticosteroids or other anti-inflammatory therapies were analyzed. The median CRP in HLH patients was lower than AOSD (71 mg/L vs. 172 mg/L, p < 0.001) and CCS (71 mg/L vs. 121 mg/L, p = 0.0095) patients. Serum ferritin levels were lower in CCS compared to HLH (1,386 µg/L vs. 29,019 µg/L, p < 0.001) and AOSD (11,359 µg/L vs. 29,019 µg/L, p = 0.035). A CRP < 130 mg/L when combined with an HScore > 136 improves the specificity of HScore alone for HLH from 85.2 to 96.3%. Adding CRP < 130 mg/L to ferritin > 15,254 µg/L increases specificity for HLH from 88.9 to 100%. This study demonstrates that median CRP is lower in HLH than in AOSD and CCS, and median ferritin is lower in CCS than in HLH or AOSD. This study demonstrates the clinical utility of these widely available inflammatory markers for distinguishing between different cytokine storm syndromes.
- Open Access
- 9 October 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (30) , e2401936
Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid
Many patients cannot tolerate low‐dose weekly methotrexate (MTX) therapy for inflammatory arthritis treatment due to life‐threatening toxicity. Although biologics offer a target‐specific therapy, it raises the risk of serious infections and even cancer due to immune system suppression. We introduce an anti‐inflammatory arthritis MTX ester prodrug using a long‐circulating biocompatible polymeric macromolecule: folic acid (FA) functionalized hyperbranched polyglycerol (HPG). In vitro the drug MTX is incrementally released through pH and enzymatic degradation over 2 weeks. The role of matrix metalloproteinases (MMPs) in site‐specific prodrug activation was verified using synovial fluid (SF) of 26 rheumatology patients and 4 healthy controls. Elevated levels of specific MMPs‐markers of joint inflammation‐positively correlated with enhanced prodrug release explained by acid‐catalyzed hydrolysis of esters by proteases. Intravenously administered 111In‐radiolabeled prodrug confirmed by SPECT/CT imaging that it accumulated preferentially in inflamed joints while reducing off‐target side‐effects in a mouse model of rheumatoid arthritis (RA). Added FA as a targeting vector prolonged prodrug action; prodrug with 4x less MTX applied every 2 weeks was as effective as weekly MTX therapy. The preclinical results suggest a prodrug‐based strategy for the treatment of inflammatory joint diseases, with potential for other chronic inflammatory diseases and cancer.
- 9 October 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (30) , e2401936
Open AccessProdrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid
Many patients cannot tolerate low‐dose weekly methotrexate (MTX) therapy for inflammatory arthritis treatment due to life‐threatening toxicity. Although biologics offer a target‐specific therapy, it raises the risk of serious infections and even cancer due to immune system suppression. We introduce an anti‐inflammatory arthritis MTX ester prodrug using a long‐circulating biocompatible polymeric macromolecule: folic acid (FA) functionalized hyperbranched polyglycerol (HPG). In vitro the drug MTX is incrementally released through pH and enzymatic degradation over 2 weeks. The role of matrix metalloproteinases (MMPs) in site‐specific prodrug activation was verified using synovial fluid (SF) of 26 rheumatology patients and 4 healthy controls. Elevated levels of specific MMPs‐markers of joint inflammation‐positively correlated with enhanced prodrug release explained by acid‐catalyzed hydrolysis of esters by proteases. Intravenously administered 111In‐radiolabeled prodrug confirmed by SPECT/CT imaging that it accumulated preferentially in inflamed joints while reducing off‐target side‐effects in a mouse model of rheumatoid arthritis (RA). Added FA as a targeting vector prolonged prodrug action; prodrug with 4x less MTX applied every 2 weeks was as effective as weekly MTX therapy. The preclinical results suggest a prodrug‐based strategy for the treatment of inflammatory joint diseases, with potential for other chronic inflammatory diseases and cancer.
- Open Access
- 10 July 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (5) , 576-583
CRP and sCD25 help distinguish between adult‐onset Still's disease and HLH
Objective: Adult‐onset Still's disease (AOSD) and secondary hemophagocytic lymphohistiocytosis (sHLH) are both hyperferritinemic cytokine storm syndromes that can be difficult to distinguish from each other in hospitalized patients. The objective of this study was to compare the inflammatory markers ferritin, D‐dimer, C‐reactive protein (CRP), and soluble CD25 (sCD25) in patients with AOSD and sHLH. These four markers were chosen as they are widely available and represent different aspects of inflammatory diseases: macrophage activation (ferritin); endothelialopathy (D‐dimer); interleukin‐1/interleukin‐6/tumour necrosis factor elevation (CRP) and T cell activation (sCD25).Methods: This was a single‐center retrospective study. Patients diagnosed by the Hematology service at Vancouver General Hospital for AOSD or sHLH from 2009 to 2023 were included.Results: There were 16 AOSD and 44 sHLH patients identified. Ferritin was lower in AOSD than HLH (median 11 360 μg/L vs. 29 020 μg/L, p = .01) while D‐dimer was not significantly different (median 5310 mg/L FEU vs. 7000 mg/L FEU, p = .3). CRP was higher (median 168 mg/L vs. 71 mg/L, p <.01) and sCD25 was lower (median 2220 vs. 7280 U/mL, p = .004) in AOSD compared to HLH. The combined ROC curve using CRP >130 mg/L and sCD25< 3900 U/mL to distinguish AOSD from HLH had an area under the curve (AUC) of 0.94 (95% confidence interval 0.93–0.97) with sensitivity 91% and specificity 93%.Conclusions: These findings suggest that simple, widely available laboratory tests such as CRP and sCD25 can help clinicians distinguish AOSD from HLH in acutely ill adults with extreme hyperferritinemia. Larger studies examining a wider range of clinically available inflammatory biomarkers in a more diverse set of cytokine storm syndromes are warranted.
- 10 July 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (5) , 576-583
Open AccessCRP and sCD25 help distinguish between adult‐onset Still's disease and HLH
Objective: Adult‐onset Still's disease (AOSD) and secondary hemophagocytic lymphohistiocytosis (sHLH) are both hyperferritinemic cytokine storm syndromes that can be difficult to distinguish from each other in hospitalized patients. The objective of this study was to compare the inflammatory markers ferritin, D‐dimer, C‐reactive protein (CRP), and soluble CD25 (sCD25) in patients with AOSD and sHLH. These four markers were chosen as they are widely available and represent different aspects of inflammatory diseases: macrophage activation (ferritin); endothelialopathy (D‐dimer); interleukin‐1/interleukin‐6/tumour necrosis factor elevation (CRP) and T cell activation (sCD25).Methods: This was a single‐center retrospective study. Patients diagnosed by the Hematology service at Vancouver General Hospital for AOSD or sHLH from 2009 to 2023 were included.Results: There were 16 AOSD and 44 sHLH patients identified. Ferritin was lower in AOSD than HLH (median 11 360 μg/L vs. 29 020 μg/L, p = .01) while D‐dimer was not significantly different (median 5310 mg/L FEU vs. 7000 mg/L FEU, p = .3). CRP was higher (median 168 mg/L vs. 71 mg/L, p <.01) and sCD25 was lower (median 2220 vs. 7280 U/mL, p = .004) in AOSD compared to HLH. The combined ROC curve using CRP >130 mg/L and sCD25< 3900 U/mL to distinguish AOSD from HLH had an area under the curve (AUC) of 0.94 (95% confidence interval 0.93–0.97) with sensitivity 91% and specificity 93%.Conclusions: These findings suggest that simple, widely available laboratory tests such as CRP and sCD25 can help clinicians distinguish AOSD from HLH in acutely ill adults with extreme hyperferritinemia. Larger studies examining a wider range of clinically available inflammatory biomarkers in a more diverse set of cytokine storm syndromes are warranted.
- 26 March 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2279-2292
A scoping review of triage approaches for the referral of patients with suspected inflammatory arthritis, from primary to rheumatology care
We aimed to (1) identify existing triage approaches for referral of patients with suspected inflammatory arthritis (IA) from primary care physicians (PCP) to rheumatologists, (2) describe their characteristics and methodologies for clinical use, and (3) report their level of validation for use in a publicly funded healthcare system. The comprehensive search strategy of multiple databases up to October 2023 identified relevant literature and focussed on approaches applied at the PCP–Rheumatologist referral stage. Primary, quantitative studies, reported in English were included. Triage approaches were grouped into patient conditions as defined by the authors of the reports, including IA, its subtypes and combinations. 13952 records were identified, 425 full text reviewed and 55 reports of 53 unique studies were included. Heterogeneity in disease nomenclature and study sample pretest probability was found. The number of published studies rapidly increased after 2012. Studies were mostly from Europe and North America, in IA and Axial Spondyloarthritis (AxSpa). We found tools ranging the continuum of development with those best performing, indicated by the area under the receiver operating curve (AUC) >0.8), requiring only patient-reported questions. There were AUCs for some tools reported from multiple studies, these were in the outstanding to excellent range for the Early IA Questionnaire (EIAQ) (0.88 to 0.92), acceptable for the Case Finding AxSpa (CaFaSpa) (0.70 to 0.75), and poor to outstanding for the Psoriasis Epidemiology Screening Tool (PEST) (0.61 to 0.91). Given the clinical urgency to improve rheumatology referrals and considering the good
- 26 March 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2279-2292
A scoping review of triage approaches for the referral of patients with suspected inflammatory arthritis, from primary to rheumatology care
We aimed to (1) identify existing triage approaches for referral of patients with suspected inflammatory arthritis (IA) from primary care physicians (PCP) to rheumatologists, (2) describe their characteristics and methodologies for clinical use, and (3) report their level of validation for use in a publicly funded healthcare system. The comprehensive search strategy of multiple databases up to October 2023 identified relevant literature and focussed on approaches applied at the PCP–Rheumatologist referral stage. Primary, quantitative studies, reported in English were included. Triage approaches were grouped into patient conditions as defined by the authors of the reports, including IA, its subtypes and combinations. 13952 records were identified, 425 full text reviewed and 55 reports of 53 unique studies were included. Heterogeneity in disease nomenclature and study sample pretest probability was found. The number of published studies rapidly increased after 2012. Studies were mostly from Europe and North America, in IA and Axial Spondyloarthritis (AxSpa). We found tools ranging the continuum of development with those best performing, indicated by the area under the receiver operating curve (AUC) >0.8), requiring only patient-reported questions. There were AUCs for some tools reported from multiple studies, these were in the outstanding to excellent range for the Early IA Questionnaire (EIAQ) (0.88 to 0.92), acceptable for the Case Finding AxSpa (CaFaSpa) (0.70 to 0.75), and poor to outstanding for the Psoriasis Epidemiology Screening Tool (PEST) (0.61 to 0.91). Given the clinical urgency to improve rheumatology referrals and considering the good
- 16 August 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1432-1436
Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients
Objectives: To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting. Methods: All patients with refractory inflammatory myositis treated with tofacitinib from a single urban centre in Vancouver, British Columbia, Canada, were included from June 2016 to December 2022. The medical records of these patients were retrospectively reviewed. Results: A total of 41 patients were included, 23 with classic DM, 12 with amyopathic DM (ADM) and six with PM phenotype. The patients failed an average of four to five non-steroidal immunosuppressants before initiation of tofacitinib. In the classic DM and ADM group, tofacitinib offered clinically and statistically significant cutaneous improvement. In all myositis patients including the PM phenotype, no meaningful muscle strength response to tofacitinib was observed. 53.7% of the patients discontinued tofacitinib due to lack of benefit or death. Of the 19 patients who remained on tofacitinib at the conclusion of this study, tofacitinib demonstrated clinically and statistically significant improvement in cutaneous disease activity. Conclusion: Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed.
- 16 August 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (5) , 1432-1436
Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients
Objectives: To evaluate the efficacy and safety of tofacitinib in treatment-refractory inflammatory myositis in a real-world clinical setting. Methods: All patients with refractory inflammatory myositis treated with tofacitinib from a single urban centre in Vancouver, British Columbia, Canada, were included from June 2016 to December 2022. The medical records of these patients were retrospectively reviewed. Results: A total of 41 patients were included, 23 with classic DM, 12 with amyopathic DM (ADM) and six with PM phenotype. The patients failed an average of four to five non-steroidal immunosuppressants before initiation of tofacitinib. In the classic DM and ADM group, tofacitinib offered clinically and statistically significant cutaneous improvement. In all myositis patients including the PM phenotype, no meaningful muscle strength response to tofacitinib was observed. 53.7% of the patients discontinued tofacitinib due to lack of benefit or death. Of the 19 patients who remained on tofacitinib at the conclusion of this study, tofacitinib demonstrated clinically and statistically significant improvement in cutaneous disease activity. Conclusion: Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed.
- 23 December 2022
- Published by Springer Nature in Skeletal Radiology
- Vol. 52 (8) , 1599-1604
Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report
We describe a case of chronic tophaceous gout affecting the spine, hands, elbows, feet, and knees in a 67-year-old man with serum urate levels at 549 µmol/L whose response to treatment was successfully mapped using dual-energy computed tomography (DECT). The patient presented with exacerbation of acute-on-chronic lumbar back pain. He had received a diagnosis of gout 3 years prior to this presentation yet was not on any urate-lowering therapy. The patient received febuxostat 80 mg and colchicine 0.3 mg once daily and underwent DECT to assess baseline monosodium urate (MSU) burden. At baseline, MSU deposits were seen in the hands, elbows, feet, knees, and lumbar spine including the left L5–S1 facet joint encroaching onto the neural foramen. After 2.5 years of treatment, serum urate level was within the target range (< 360 µmol/L), and the patient underwent a follow-up DECT that revealed almost full resolution of MSU deposition in the spine, including the MSU-burdened facet joint and neural foramen in the lumbar spine, in addition to all the affected peripheral joints. This case is the first report of radiological evidence of nearly complete resolution of MSU deposits in spinal gout on DECT after urate-lowering therapy treatment, which demonstrates the utility of this imaging modality as a non-invasive investigational point-of-care imaging modality for mapping treatment response and identifying the etiology of back pain in a patient with chronic tophaceous spinal gout.
- 23 December 2022
- Published by Springer Nature in Skeletal Radiology
- Vol. 52 (8) , 1599-1604
Assessing tophaceous spinal gout treatment response using dual-energy CT as a point-of-care imaging modality: case report
We describe a case of chronic tophaceous gout affecting the spine, hands, elbows, feet, and knees in a 67-year-old man with serum urate levels at 549 µmol/L whose response to treatment was successfully mapped using dual-energy computed tomography (DECT). The patient presented with exacerbation of acute-on-chronic lumbar back pain. He had received a diagnosis of gout 3 years prior to this presentation yet was not on any urate-lowering therapy. The patient received febuxostat 80 mg and colchicine 0.3 mg once daily and underwent DECT to assess baseline monosodium urate (MSU) burden. At baseline, MSU deposits were seen in the hands, elbows, feet, knees, and lumbar spine including the left L5–S1 facet joint encroaching onto the neural foramen. After 2.5 years of treatment, serum urate level was within the target range (< 360 µmol/L), and the patient underwent a follow-up DECT that revealed almost full resolution of MSU deposition in the spine, including the MSU-burdened facet joint and neural foramen in the lumbar spine, in addition to all the affected peripheral joints. This case is the first report of radiological evidence of nearly complete resolution of MSU deposits in spinal gout on DECT after urate-lowering therapy treatment, which demonstrates the utility of this imaging modality as a non-invasive investigational point-of-care imaging modality for mapping treatment response and identifying the etiology of back pain in a patient with chronic tophaceous spinal gout.
- 15 August 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (2) , 290-291
Adult-Onset Still Disease After ChAdOx1 nCOV-19 Vaccination
We report a case of adult-onset Still disease (AOSD) after ChadOx1 nCOV-19/AZD1222 coronavirus disease 2019 (COVID-19) vaccine (AstraZeneca). A 51-year-old female received her first AZD1222 vaccine in spring of 2021.
- 15 August 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (2) , 290-291
Adult-Onset Still Disease After ChAdOx1 nCOV-19 Vaccination
We report a case of adult-onset Still disease (AOSD) after ChadOx1 nCOV-19/AZD1222 coronavirus disease 2019 (COVID-19) vaccine (AstraZeneca). A 51-year-old female received her first AZD1222 vaccine in spring of 2021.